



Original article

Hypolipidemic and hepato-protective effects of Alchornea *cordifolia leaf* extract in streptozotocin-induced diabetic rats

R.K. Mohammed^a,*, E.D. Eze^b, S. Ibrahim^a, S.E. Atawodi^a, A. Shaibu^b, M.N. Ugwu^c, I.J. Momoh^b, O. Onaadepo^d

^aDepartment of Biochemistry, Faculty of Science Ahmadu Bello University, Zaria, Nigeria.

^bDepartment of Human Physiology, Faculty of Medicine, Ahmadu Bello University,Zaria, Nigeria.

Contents lists available at Sjournals

Journal homepage: www.Sjournals.com

Scientific Journal of edical Science

^cDepartment of Medical Biochemistry, Faculty of Basic Medical Sciences, Cross River University of Technology, Calabar, Nigeria.

^aDepartment of Physiology, College of Health Sciences, University of Abuja, Abuja, Nigeria.

^{*}Corresponding author; Department of Biochemistry, Faculty of Science Ahmadu Bello University, Zaria, Nigeria.

ARTICLEINFO

Article history: Received 10 April 2013 Accepted 20 May 2013 Available online 28 May 2013

Keywords:

Alchornea cordifolia Alanine aminotransaminase Alkaline phosphatase Aspartate aminotransaminase Total cholesterol Diabetes mellitus Low density lipoprotein Triglyceride

ABSTRACT

The study investigated the hypolipidemic and hepatoprotective effects of n-butanol fraction of Alchornea cordifolia leaf extract in streptozotocin-induced diabetic rats. To achieve this set objective, 16 hours fasted rats were made diabetic by single intraperitoneal injection of 60 mg/kg body weight dose of streptozotocin dissolved in 0.1 ml fresh cold citrate buffer pH 4.5. After this, the diabetic animals were randomly divided into the following groups: Group I served as the normal control, Group II served as diabetic control, while Group III to Group VI were treated with 200, 400 and 800mg/kg b w of the plant extract fraction and glibenclamide 10mg/kg b w respectively by oral gavage for a period of 4 weeks. At the end of treatment period all animals from each group were euthanized and blood samples collected by cardiac puncture. There was a statistically significant (p< 0.05) reduction in blood glucose level in all groups treated with 200, 400 and 800mg/kg b w of the extract after day 7, 14, 21 and 28 when compared to the diabetic control group. The study also revealed a significantly decreased (p<0.05) serum total cholesterol, triglyceride and low-density lipoprotein and significantly elevated (p<0.05) serum levels especially in the groups treated with 400 and 800 mg/kg b w of the extract when compared to the diabetic control group. There was also a significantly reduced (p<0.05) serum liver enzymes, AST, ALT and ALP as well as total and direct conjugated bilirubin levels in all groups that received various doses of the plant extract when compared to the diabetic control group. It can be concluded that the plant possesses anti-diabetic property suggesting that the plant may be useful in the management of dyslipidemia, a secondary complication that usually occur in diabetic condition.

© 2013 Sjournals. All rights reserved.

1. Introduction

Diabetes mellitus is a chronic metabolic disorder with numerous complications. It is characterized by chronic high blood glucose levels leading to increased morbidity and mortality. Diabetes if not controlled results in structural and functional changes in various target tissues and organs (Fauci et al., 2008). Dyslipidemia is the major risk factors for macro vascular complications leading to cardiovascular disease (CVD) in type 2 diabetes mellitus. In addition to this, endothelial dysfunction, platelet hyperactivity, impaired fibrinolytic balance and abnormal blood flow may accelerate atherosclerosis and increased risk of thrombotic vascular events (Colwell and Nesto, 2003). Macro-vascular disease is the most common cause of morbidity and mortality especially in type 2 diabetes mellitus (Koskinen, 1998). Macro-vascular disease is defined as illnesses affecting the larger arteries supplying the heart, brain, and the legs, thereby causing ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. In patients with diabetes, alteration in distribution of lipid increased risk of atherosclerosis. Specifically, insulin resistance and insulin deficiency was identified as phenotype of dyslipidemia in diabetes mellitus (Krauss and Siri, 2004; Chahil and Ginsberg, 2006). And this is usually characterized with high plasma triglyceride, total cholesterol, LDL-cholesterol level and low HDL-cholesterol level (Mooradian, 2009). Hepato-biliary disorders, such as inflammation, necrosis or fibrosis of non-alcoholic fatty liver disease, cirrhosis, hepato-cellular carcinoma, hepatitis C, and acute liver failure are complications of diabetes (Balazs and Halmos, 1995; Tolman et al., 2004). Therefore combating diabetes mellitus goes far beyond mere glycaemic control. Streptozotocin (STZ) is frequently used to induce experimental type 1 diabetes (Yamagishi et al., 2001). The cytotoxic action of STZ is mediated by free radicals and STZ has toxic and carcinogenic effects on the pancreas, liver and kidneys (Okawa and Doi, 1983). Currently available therapies for diabetes such as insulin, sulfonylureas, biguanides, α -glucosidase inhibitors, and glinides, suffer from various adverse effects, thus, managing diabetes without any side effects is still a challenge to the workers (Saxena and Kishore, 2004), and hence the search for more effective and safer therapeutic agents in eradicating diabetic syndromes has continued to be an important area of investigation. To cope with severe problems associated with using of synthetic anti-diabetic drugs, there is a need to look for more efficacious drugs with lesser side effects and also of low cost (Goutam, 2011). Alchornea cordifolia is widespread in secondary forest and riverine forest, especially in marshy areas but sometimes in drier sites, from sea-level up to 1500 m altitude. It is commonly used as a medicinal plant throughout its area of distribution. The leaves are mostly used, but also the stem bark, stem pith, leafy stems, root bark, roots and fruits enter in local medicine (Adewunmi et al., 2001; Ebi, 2001.). In Nigeria, the leaves or leafy stems, as an infusion or chewed fresh, are taken for their sedative and antispasmodic activities to treat a variety of respiratory problems including sore throat, cough and bronchitis, genital-urinary problems including venereal diseases and female sterility, and intestinal problems including gastric ulcers, diarrhoea, amoebic dysentery and worms (Banzouzi et al., 2002). They are also taken as a blood purifier, as a tonic and to treat anaemia and epilepsy. A decoction of bruised fruit is taken to prevent miscarriage. The sap of the fruit is applied to cure eye problems and skin diseases (Obadoni and Ochuko, 2002; Osadebe and Okoye, 2003). However, its use in the management of diabete mellitus and its associated complication has not been fully elucidated. The present study was aimed at assessing the hypolipidemic and hepatoprotective effects of n-butanol fraction of Alchornea cordifolia leaf extract in streptozotocin-induced diabetic rats.

2. Materials and methods

2.1. Chemicals and drugs used

Streptozocin (STZ) was purchased from Sigma chemicals (St Louis U.S.A). Glibenclamide was purchased from pharmaceutical store in Zaria, Kaduna state, while Accu-chek Advantage a digital glucometer was used for the determination of blood glucose levels.

2.2. Plant material used

Fresh leaves of *Alchornea cordifolia* were collected from old Karu village, Karu Local government of Nasarawa State, Nigeria in the month January 2011. The plant was then taken to the herbarium unit of Biological Science Department Ahmadu Bello University, Zaria, Kaduna state, where the plant was identified by Mal. M. Musa and a voucher specimen (Number 401) deposited.

2.2.1. Plant extracts preparation

The fresh leaves Alchornea cordifolia collected were air dried under the shade and ground into fine powder. The powder (400g) was macerated in 2.0 L of distilled water at room temperature for 24 h. It was then filtered using a filter paper (Whatmann size 1). The filtrate was then was then partitioned with n-Butanol to get an n-Butanol fraction which was then evaporated to dryness in an oven at 30°C. A brownish residue weighing 8g was obtained and kept in a sealed container refrigerated until it was reconstituted.

2.2.2. Acute toxicity study of plant extract

The lethal doses (LD₅₀) of fresh leaves of Alchornea cordifolia was carried out by method of Lorke (1983).

2.2.3 Phytochemical screening of plant extract

The methods of analysis employed were those described by Beach and Turner (1975).

2.3. Animals

Strains of albino wistar rats of both sexes that weighed between 150 – 200 g were obtained from the Department of Human Physiology, Animal House, Ahmadu Bello University, Zaria. The animals were kept and maintained under laboratory condition of temperature, humidity and light. The animals allowed to acclimatized for two weeks, but were allowed free access to water, before commencement of the experiments.

2.4. Induction of experimental diabetes mellitus

Diabetes mellitus was induced by single intraperitoneal injection of 60 mg/kg body weight dose of streptozotocin dissolved in 0.1 ml fresh cold citrate buffer pH 4.5 into 16 h-fasted rats. Three days after Streptozotocin injection, blood was taken from tail artery of the rats [14]. Rats having blood glucose levels greater than 200mg/dl were considered diabetic and included in the study. The diabetic rats were then divided randomly into different groups before the commencement of treatment.

2.5. Experimental design

In the experiment, a total of 36 rats were used, the animals were divided into 6 groups of 6 rats each as follows:

Group 1: Normal control and received 1ml of distilled water Groups 2: Diabetic control and treated with 1ml of distilled water Group 3: Diabetic and received 200mg/kg b w n-butanol fraction of *A. cordifolia* leaf extract Group 4: Diabetic and received 400mg/kg b w n-butanol fraction of *A. cordifolia* leaf extract Group 5: Diabetic and received 800mg/kg b w n-butanol fraction of *A. cordifolia* leaf extract Group 6: Diabetic and received Glibenclamide 10mg/kg b w All regimens were given orally once daily by gavage for a period of 28 days.

2.6. Determination of blood glucose levels

All blood samples were collected from the tail artery of the rats after every seven days. Blood glucose levels was determined by the glucose-oxidase principle [14] using a digital glucometer (Accu-chek Advantage) and expressed in the unit of mg/dl.

2.7. Determination of lipid profile

These were determined spectrophotometrically, using enzymatic colometric assay kits (Randox Laboratories Limited kits, Unite kingdom) as follows:

2.7.1. Determination of serum total cholesterol

The serum level of total cholesterol was quantified after enzymatic hydrolysis and oxidation of the sample as described by method of Stein (1987). 1000 μ l of the reagent was added to each of the sample and standard. This was incubated for 10 minutes at 20-25 ^oC after mixing and the absorbance of the sample (A _{sample}) and standard (A _{standard}) was measured against the reagent blank within 30 minutes at 546nm.

2.7.2. Determination of serum triglyceride

The serum triglyceride level was determined after enzymatic hydrolysis of the sample with lipases as described by method of Tietz (1990). 1000 μ l of the reagent was added to each of the sample and standard. This was incubated for 10 minutes at 20-25 ⁰C after mixing and the absorbance of the sample (A _{sample}) and standard (A _{standard}) was measured against the reagent blank within 30 minutes at 546nm.

2.7.3. Determination of serum high-density lipoprotein cholesterol

The serum level of HDL-C was measured by the method of Wacnic and Albers (1978). Low-density lipoproteins (LDL and VLDL) and chylomicron fractions in the sample were precipitated quantitatively by addition of phosphotungstic acid in the presence of magnesium ions. The mixture was allowed to stand for 10 minutes at room temperature and centrifuged for 10 minutes at 4000 rpm. The supernatant represented the HDL-C fraction. The cholesterol concentration in the HDL fraction, which remained in the supernatant, was determined.

2.7.4. Determination of serum low-density lipoprotein cholesterol

The serum level of (LDL-C) was measured according to protocol of Friedewald *et al.*, (1972) using the relationship below:

LDL-C = TC-TGL/5 + HDL-C

2.8. Determination of serum liver enzymes

The serum enzymes Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and Alkaline phosphatase (ALP) were determined spectrophotometrically, using enzymatic colometric assay kits according to the laboratory procedures of Randox Laboratories Limited kits, United Kingdom.

2.9. Statistical analysis

All data obtained were expressed as mean \pm SEM. The data were statistically analyzed using one-way analysis of variance (ANOVA) with Tukey's multiple comparison post hoc tests to compare the level of significance between control and experimental groups. All statistical analysis was done using SPSS version 17.0 software. The values of p < 0.05, p < 0.01 and p < 0.001 were considered as significant.

3. Results

In the present study, treatment of the animals with various doses of n-butanol fraction of Alchornea cordifolia leaf extract showed no signs of toxicity and no deaths were recorded. Therefore, the LD_{50} of n-butanol fraction of leaf extract Alchornea cordifolia was safe at least up to the dose of 5000mg/kg b w.

Preliminary phytochemical screening of the plant extract revealed the presence of cyanogenetic glycosides, saponins, carbohydrate, flavonoids, tannins, cardiac glycosides and steroids and Triterpenoids.

Table 1 shows the mean blood glucose level of control and the experimental groups. The study revealed that the blood glucose levels did not differ significantly (p >0.05) within and between groups after day 1 when compared to the diabetic control group. But there was a statistically significant (p< 0.05) decrease in the blood glucose level in the group treated with 200, 400 and 800mg/kg b w of the plant extract after day 7, 14, 21 and 28. The effect of the extract in reducing blood glucose level was comparable to glibenclamide when compared to the diabetic control group.

Table 2 shows the mean total cholesterol, triglyceride, high density-lipoprotein and low density- lipoprotein values in all experimental and control groups respectively. There was a statistically significant (P<0.05) rise in serum total cholesterol, triglyceride, and low density-lipoprotein and significant reduction (P<0.05) in serum level of high density-lipoprotein in the diabetic control group when compared to normal control animals. *Alchornea cordifolia* administration significantly decreased (p<0.05) serum total cholesterol, triglyceride and low density-lipoprotein levels and increased serum high density-lipoprotein level in diabetic animals treated with the graded doses of extract when compared to diabetic control group; and the effect of the extract was comparable to the response seen with glibenclamide treated group at the dose tested.

Table1

Effect of n-butanol fraction of *Alchornea cordifolia* on blood glucose level in streptozotocin-induced diabetic Wistar rats.

Treatment Given	Blood glucose levels (mg/dl)					
freatment Given	Day 1	Day 7	Day 14	Day 21	Day 28	
Normal control	91.4±3.1	88.6±3.6	90.0±4.1	87.8±3.9	88.6±2.0	
Diabetic control	381.0±55.8	383.4±29.9	384.0±26.9	363.8±18.0	364.4±17.8	
n-But 200 mg/kg b w	382.4±42.0 ^{ns}	282.2±29.0 ^ª	203.0±15.6 [°]	154.2±18.5 [°]	114.0±12.9 ^ª	
n-But 400 mg/kg b w	372.6±20.3 ^{ns}	246.6±19.1 ^ª	185.8±20.2 ^ª	140.0±13.1 ^ª	102.2±5.0 [°]	
n-But 800 mg/kg b w	382.6±32.6 ^{ns}	260.8±24.9 ^ª	175.8±16.7 ^ª	120.8±6.3 ^ª	104.8±3.4 [°]	
Glibenclamide 10mg/kg b w	358.6±13.9 ^{ns}	187.0±19.6 ^a	129.0±3.8 ^a	103.0±1.9 ^ª	95.8±1.8 [°]	

Values are presented as mean \pm SEM.

Values are statistically significant compared to control group at ^a p < 0.05, while ns =not significant.

Table 2

Effect of of n-butanol fraction of Alchornea cordifolia on lipid profile in streptozotocin-induced diabetic Wistar rats.

Treatment given	Serum total cholesterol (mg/dl)	Serum triglyceride (mg/dl)	Serum HDL (mg/dl)	Serum LDL (mg/dl)
Normal control	79.29±1.65	89.00±8.18	45.48±482	16.01±3.58
Diabetic control	164.63±6.60	206.23±6.02	15.39±2.90	107.98±7.10
n-But200mg/kg b w	135.57±5.00 ^{ns}	159.33±4.46 ^ª	22.92±3.27 ^{ns}	80.78±5.57 ^{ns}
n-But400mg/kg bw	108.64±7.10 ^a	117.00±6.40 ^a	29.79±4.58 ^{ns}	55.44±6.47 ^ª
n-But800 mg/kg bw	91.73±9.36 ^a	107.79±7.08 ^ª	34.61±3.67 ^ª	35.56±7.37 ^ª
Glibenclamide 10 mg/kg bw	105.42±9.57 ^a	107.41±16.40 ^a	35.14±4.13 [°]	48.79±6.17 ^a
Glibenclamide 10 mg/kg bw		107.41±16.40	35.14±4.13	48.79±6.17

Values are presented as mean ± SEM.

Values are statistically significant compared to control group at ^a p < 0.05, while ns =not significant.

Table 3

Effect of n-butanol fraction of *Alchornea cordifolia* on serum liver enzymes in streptozotocin-induced diabetic Wistar rats.

Treatment given	ALT (IU/L)	AST (IU/L)	ALP (IU/L)					
Normal control	40.40±2.24	145.92±2.40	37.37±2.74					
Diabetic control	99.00±3.44	220.60±10.04	96.23±4.26					
n-But200 mg/kg bw	64.66±5.58 ^ª	166.10±6.62 ^ª	56.73±6.050 ^a					
n-But400 mg/kg b w	55.68 ± 6.58^{a}	143.41±3.78 ^ª	31.97±3.33 ^a					
n-But800 mg/kg b w	44.50±2.18 ^a	143.50±11.56 [°]	58.16±3.68 ^a					
Glibenclamide 10 mg/kg b w	46.80±6.44 ^ª	133.64±6.06 ^ª	39.37±8.00 ^a					

Values are presented as mean ± SEM Values are statistically significant compared to control group

at ^a p<0.05 while ns =not significant.

Table 3 shows the mean aspartate aminotransaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) values in all experimental and control groups respectively. There was a statistically significant (p<0.05) rise in the level of serum AST, ALT and ALP in the diabetic control group compared to the non diabetic control animals. However, the study revealed the plant extract at doses tested significantly decreased (p<0.05) serum level of AST, ALT and ALP when compared with diabetic control group.

4. Discussion

Diabetes mellitus is a serious risk factor for the development of multiple organ damage as a result of multiple and complex mechanisms. The intention of this study was to evaluate the ability of Alchornea cordifolia to protect against changes that occur in the liver and lipid abnormalities which is one of the most common metabolic complications of diabetes mellitus which is found in about 40% of diabetics (Ravi et al., 2005; Eze et al., 2012). Administration of Alchornea cordifolia leaf extract to the diabetic animals significantly reduced the blood glucose level in the group treated with 200mg/kg b w with a greater decrease recorded with 400 and 800mg/kg b w when compared to the diabetic control group. Preliminary phytochemical screening of n- butanol fraction of leaf extract of Alchornea cordifolia revealed the presence of flavonoids and saponins among other secondary metabolites. Flavonoids have been reported to exert its anti-diabetic activity by inhibiting sodium-dependent glucose transporter Isoform 2 (Glut 2), the intestinal transporters for glucose, therefore it is also likely that it might reduce blood glucose level by inhibiting the glucose absorption from the intestine with consequent reduction in the blood glucose concentration as was observed in this present work (Song et al., 2002). The levels of serum triglyceride and cholesterol are usually elevated in diabetic patients (Patel, 2008). The hyperlipidemia mainly occurs as a result of insulin deficiency and thereby affecting metabolic processes like lipolysis and lipogenesis (Arner, 2005). The result of the present study showed increased serum level of cholesterol, triglyceride, low-density and depleted serum concentration of high-density lipoprotein in streptozotocin treated animals. This results support the findings of Mendez and Balderas (2001) that reported increased plasma cholesterol, triglycerides, LDLC and decreased HDL-C in streptozocin-induced hyperglycemia in rats. Alchornea cordifolia administration significantly decreased serum total cholesterol, triglyceride and low density-lipoprotein levels and increased high density-lipoprotein in the STZinduced animals at all doses and this was comparable to the response seen with glibenclamide treatment at the doses tested. However, this beneficial effect of the plant extract on the lipid profile may be secondary to glycaemic control. In addition, the stabilization of serum triglyceride and cholesterol levels in diabetic animals by the plant extract may be attributed to glucose utilization and hence depressed mobilization of fat (Iweala and Oludare, 2011). AST and ALT are important and critical enzymes in the biological processes (Maiti et al., 2004). Measurements of serum ALT and AST are used in the evaluation of liver damage. Elevation of these enzyme activities is considered as evidence for hepatic damage (Schindhelm et al., 2006). Consequently, they are considered specific indicators for liver damage (El-demerdash et al., 2002). In our study, there was a significantly elevated serum ALT, AST, ALP and total and direct conjugated bilirubin activities of diabetic rats when compared with the normal control rats. The significantly decreased activities of these enzymes upon treatment with various doses of the plant extract showed the protective effect of the extract against liver damage and therefore can improve prognosis of diabetic patients.

5. Conclusion

In conclusion, the present study demonstrated the anti-diabetic activity of *Alchornea cordifolia* through its anti-hyperlipidemic and hepato-protective effects, hence lend credence to the traditional use of this plant in the management of diabetes mellitus and its secondary complications.

Reference

- Adewunmi, C.O., Agbedahunsi, J.M., Adebajo, A.C., Aladesanmi, A.J., Murphy, N., Wando, J., 2001. Ethnoveterinary medicine: screening of Nigerian medicinal plants for trypanocidal properties. *Journal of Ethnopharmacology*, 77, 19–24.
- Arner, P., 2005. "Human fat cell lipolysis: biochemistry, regulation and clinical role," *Best Practice Research Clinical Endocrinology Metabolism*, 19 (4), pp. 471-482.

- Balazs, M., Halmos, T., 1995. Electron microscopic study of liver fibrosis associated with diabetes mellitus. *Exp Pathol*.27,153–62.
- Banzouzi, J.T., Prado, R., Menan, H., Valentin, A., Roumestan, C., Mallie, M., Pelissier, Y., Blache, Y., 2002. In vitro antiplasmodial activity of extracts of Alchornea cordifolia and identification of an active constituent: ellagic acid. *Journal of Ethnopharmacology*, 81, 399–401.
- Beach, E. F., Turner, J.J., 1958. An enzymatic method for glucose determination uptake in body fluids, *Clinical Chemistry*, 14, 462-468.
- Burcelin R, Eddouks, M., Maury, J., Kande, J., Assan, R., Girard, J., 1995., Excessive glucose production, rather than Insulin resistance, account for hyperglycemia in recent onset streptozocin-diabetic rats, *Diabetologia*, 35, 283-290.
- Chahil, T.J., Ginsberg, H.N., 2006. Diabetic dyslipidemia. *Endocrinol Metab Clin North Am* 35(3), pp. 491–510.
- Colwell, J.A., Nesto, R.W., 2003. The platelet in diabetes: focus on prevention of ischemic events. *Diabetes Care*, 26(7), pp. 2181–2188.
- Ebi, G.C., 2001. Antimicrobial activities of *Alchornea cordifolia*. *Fitoterapia* 72, 69–72.
- El-Demerdash, F. M., Yousef, M.I., Elagamy, E. I., 2002. Influence of paraquat, glyphosate, and cadmium on the activity of some serum enzymes and protein electrophoretic behavior (in vitro). *Endocrinology & Metabolism*, 5(3), pp. 150-159.
- Eze, E. D., Mohammed, A., Musa, K.Y., Tanko, Y., Isa, A.S., 2012. Effect of Ethanolic Leaf Extract of *Mucuna pruriens* (*fabaceae*) on Lipid Profile inAlloxan-Induced Diabetic Wistar rats *British Journal of Pharmacology and Toxicology* 3(3), 102-109, 2012.
- Fauci, A.S., Braunwald, E., Kasper, D.L., Hauser, D.L., 2008. Chapter 338; Diabetes Mellitus, Harrison's Principles of Internal Medicine, 17th Edition The McGraw-Hill Companies, Inc..*Foundation Newsletter* 1, 3, ISSN 1755-3245.
- Friedewald, W. T., Levy, R., Fradrickson, D.S., 1972. Estimation of concentration of Low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugation. *Clinical Chemistry*.19; 449-452.
- Goutam, B., 2011. 6. Bio-flavonoids with promising antidiabetic potentials: A critical survey. *Opportunity, Challenge and Scope of Natural Products in Medicinal Chemistry*, 187-212.
- Iweala, E.E.J., Oludare, F.D., 2011. Hypoglycemic effect, biochemical and histological changes of *Spondiasmombin Linn.* and *parinaripolyandrabenth*. Seed ethanolic extracts in alloxan-induced diabetic rats. *J. pharmacol. Toxicol.*, 6,101-112.
- Koskinen, S.V., Reunanen, A.R., Martelin, T. P., Valkonen, T., 1998. Mortality in a large Krauss, R.M. and P. W. Siri, 2004. Dyslipidemia in type 2 diabetes. *Med Clin North Am* 88(4), pp. 897–909.
- Lorke, D., 1983. A new approach to practical acute toxicity testing, *Archive of Toxicology*, 54, 275-287.
- Maiti, R., D. Jana, U.D., Ghosh, D., 2004. Antidiabetic effect of aqueous extract of seed of *Tamarindus indica* in streptozotocin-induced diabetic rats. *J Ethnopharmacol.* 92,85-91.
- Mendez, J.D., Balderas, F., 2001. Regulation of hyperglycemia and dyslipidemia by exogenous Largininein diabetic rats. *Biochimie*, 83(5), 453-458.
- Mooradian, A.D., 2009. Dsylipidemia in type 2 diabetes mellitus. Nature Clinical Practice J Environ Sci Health, 36, 29-42.
- Obadoni, B.O., Ochuko, P.O., 2002. Phytochemical studies and comparative efficacy of the crude extracts of some haemostatic plants in Edo and Delta States of Nigeria. *Global Journal of Pure and Applied Sciences*, 8(2), 203–208.
- Okawa, H., Doi, K., 1983. Neoplastic lesions in Streptozotocin treated rats. *Jikken Dobutsu*, 32, 77–84.
- Osadebe, P.O., Okoye, F.B.C., 2003. Anti-inflammatory effects of crude methanolic extract and fractions of *Alchornea cordifolia* leaves. *Journal of Ethnopharmacology* 89, 19–24.
- Patel, J., 2008. "Diabetes: managing dyslipidaemia," Clinical Evidence, Vol. 2008 pp. 0610.
- Ravi, K., Rajasekaran, S., Subramanian, S., 2005. Antihyperglycemic effect of *Eugenia jambolana* seed kernel on streptozotocin-induced diabetes in rats. *Food Chem. Toxicology*, 43, 1433 1439.
- Saxena, A., Vikram, N.K., 2004. Role of selected Indian plants in management of type 2 diabetes: a review. *The Journal of Alternative and Complementary Medicine* 10, 369 378.
- Schindhelm, R.K., Diamant, M., Dekker, J.M., Tushuizen, M.E., Teerlink, T., Heine, R.J., 2006. "Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease," *Diabetes Metabolism Research and Reviews*, 22(6), pp. 437-443.

- Song, J., Kwon, O., Chen, S., Daruwala, R., Eck, P., Park, J.B., 2002. Flavonoid inhibition of Sodium-dependent Vitamin C transport 1 (SVCT 1) and Glucose Transporter Isoform 2 (GLUT 2), intestinal transporters for vitaminC and glucose. *Journal of Biological Chemistry*, 277,15252-60.
- Stein, E.A., 1987. Lipids, lipoproteins and Apolipoproteins. In: Treitz, N. W. (Ed). Fundamentals of Clinical Chemistry. 3rd Edn., W. B Sauders Philadelphia, pp; 470-479.
- Tietz, N.W., 1990. Clinical Guide to Laboratory Test, Second Edition W.B. Saunders Company, Philadelphia, U.S.A. 554-556.
- Tolman, K.G., Fonseca, V., Tana, M.H., Dalpiaz, A., 2004. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. *Ann Intern Med*;141, 946–56.
- Wacnic, R.G.J., Alber, J.J., 1978. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high density lipoprotein cholestsrol. *Journal of Lipid Research*, 19, 65-76.
- Yamagishi, N., Nakayama, K., Wakatsuki, T., Hatayama, T., 2001. Characteristic changes of stress protein expression in streptozotocin-induced diabetic rats. *Life Sci.* 69, 2603–9.